We use cookies to store user preferences and to anonymously track visitors for analytics. Some cookies are essential and can't be turned off. If you would like to allow all cookies please click Accept otherwise click Decline to disable all but essential cookies. For more information please view our Privacy Policy.
Motor and nonmotor symptoms significantly worsened in the COVID‐19 group, requiring therapy adjustment in one‐third of cases. Clinical deterioration was explained by both infection‐related mechanisms and impaired pharmacokinetics of dopaminergic therapy. Urinary issues and fatigue were the most prominent nonmotor issues. Cognitive functions were marginally involved, while none experienced autonomic failure.
Read more in Movement Disorders 2020 Aug. Vol. 35(8); 1287-1292
doi: 10.1002/mds.28170
Copyright © 2020 EPDA. All Rights Reserved
Back to top